Thomas Hallam

Thomas Hallam is a Senior Scientist II at Novartis Institutes for BioMedical Research (NIBR), where research focuses on novel targets and technology for treating retinal disease. Hallam has a robust background, having served as a Senior Research Associate at Gyroscope Therapeutics, and previously held postdoctoral positions at Newcastle University and Catalyst Biosciences. Hallam's academic credentials include a PhD from Newcastle University, awarded for work on the genetic aspects of age-related macular degeneration, and a Master's in Neuroscience from the University of Southampton. Additionally, Hallam has experience in undergraduate research, working on neurodegenerative diseases and advanced imaging techniques.